CN114558014B - PRMT5 inhibitor and application thereof in treating breast cancer - Google Patents
PRMT5 inhibitor and application thereof in treating breast cancer Download PDFInfo
- Publication number
- CN114558014B CN114558014B CN202210334932.4A CN202210334932A CN114558014B CN 114558014 B CN114558014 B CN 114558014B CN 202210334932 A CN202210334932 A CN 202210334932A CN 114558014 B CN114558014 B CN 114558014B
- Authority
- CN
- China
- Prior art keywords
- prmt5
- tadalafil
- compounds
- breast cancer
- doxorubicin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010006187 Breast cancer Diseases 0.000 title claims abstract description 17
- 208000026310 Breast neoplasm Diseases 0.000 title claims abstract description 17
- 229940125897 PRMT5 inhibitor Drugs 0.000 title claims abstract description 16
- 150000001875 compounds Chemical class 0.000 claims abstract description 52
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims abstract description 50
- 102100034607 Protein arginine N-methyltransferase 5 Human genes 0.000 claims abstract description 32
- 101710084427 Protein arginine N-methyltransferase 5 Proteins 0.000 claims abstract description 32
- 229960004679 doxorubicin Drugs 0.000 claims abstract description 25
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 17
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims abstract description 13
- 229960004316 cisplatin Drugs 0.000 claims abstract description 13
- 230000000259 anti-tumor effect Effects 0.000 claims abstract description 11
- 229940044683 chemotherapy drug Drugs 0.000 claims abstract description 11
- 230000035755 proliferation Effects 0.000 claims abstract description 7
- 239000003112 inhibitor Substances 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 3
- 229960000835 tadalafil Drugs 0.000 abstract description 39
- 230000006907 apoptotic process Effects 0.000 abstract description 13
- 238000001727 in vivo Methods 0.000 abstract description 5
- 238000011160 research Methods 0.000 abstract description 4
- 238000012216 screening Methods 0.000 abstract description 4
- -1 Tadalafil derivative compounds Chemical class 0.000 abstract description 3
- 238000000338 in vitro Methods 0.000 abstract description 3
- 229940041181 antineoplastic drug Drugs 0.000 abstract description 2
- 238000011960 computer-aided design Methods 0.000 abstract description 2
- 238000002474 experimental method Methods 0.000 abstract description 2
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 abstract 1
- WOXKDUGGOYFFRN-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C(C4=CC=CC=C4N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 WOXKDUGGOYFFRN-IIBYNOLFSA-N 0.000 description 39
- 210000004027 cell Anatomy 0.000 description 27
- 238000006243 chemical reaction Methods 0.000 description 15
- 238000000034 method Methods 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 230000000694 effects Effects 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 9
- 230000003833 cell viability Effects 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 238000003032 molecular docking Methods 0.000 description 8
- FAQDUNYVKQKNLD-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 description 8
- 229960000572 olaparib Drugs 0.000 description 8
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 108090000672 Annexin A5 Proteins 0.000 description 4
- 102000004121 Annexin A5 Human genes 0.000 description 4
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229940127089 cytotoxic agent Drugs 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 229920002521 macromolecule Polymers 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 3
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 3
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- YDGMGEXADBMOMJ-LURJTMIESA-N N(g)-dimethylarginine Chemical compound CN(C)C(\N)=N\CCC[C@H](N)C(O)=O YDGMGEXADBMOMJ-LURJTMIESA-N 0.000 description 3
- HVPFXCBJHIIJGS-LURJTMIESA-N N(omega),N'(omega)-dimethyl-L-arginine Chemical compound CN\C(=N/C)NCCC[C@H](N)C(O)=O HVPFXCBJHIIJGS-LURJTMIESA-N 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 3
- 238000001308 synthesis method Methods 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 101100434927 Caenorhabditis elegans prmt-5 gene Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 101000582546 Homo sapiens Methylosome protein 50 Proteins 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 102100030528 Methylosome protein 50 Human genes 0.000 description 2
- 102000003708 Protein arginine N-methyltransferase Human genes 0.000 description 2
- 108020000912 Protein arginine N-methyltransferase Proteins 0.000 description 2
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 2
- 101000985737 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Protein arginine N-methyltransferase HSL7 Proteins 0.000 description 2
- 101000651946 Schizosaccharomyces pombe (strain 972 / ATCC 24843) Protein arginine N-methyltransferase skb1 Proteins 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 229960001570 ademetionine Drugs 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000012137 double-staining Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000009510 drug design Methods 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- XNFNGGQRDXFYMM-UHFFFAOYSA-N hydron;methyl 2-amino-3-(1h-indol-3-yl)propanoate;chloride Chemical compound [Cl-].C1=CC=C2C(CC([NH3+])C(=O)OC)=CNC2=C1 XNFNGGQRDXFYMM-UHFFFAOYSA-N 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
- 210000001503 joint Anatomy 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- ZKXZLIFRWWKZRY-KRWDZBQOSA-N n-[(2s)-3-(3,4-dihydro-1h-isoquinolin-2-yl)-2-hydroxypropyl]-6-(oxetan-3-ylamino)pyrimidine-4-carboxamide Chemical compound C([C@H](O)CN1CC2=CC=CC=C2CC1)NC(=O)C(N=CN=1)=CC=1NC1COC1 ZKXZLIFRWWKZRY-KRWDZBQOSA-N 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- HBGHQRGHFNTSDP-DJABAAGCSA-N (1S,2S,3S,5R)-3-[[6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl]oxy]-5-(4-methylpyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol Chemical compound CC1=NC=NC2=C1C=CN2[C@@H]1C[C@H](OC2=C3CNCCC3=C(F)C(=C2)C(F)F)[C@@H](O)[C@H]1O HBGHQRGHFNTSDP-DJABAAGCSA-N 0.000 description 1
- YPJMOVVQKBFRNH-UHFFFAOYSA-N 1-(9-ethylcarbazol-3-yl)-n-(pyridin-2-ylmethyl)methanamine Chemical compound C=1C=C2N(CC)C3=CC=CC=C3C2=CC=1CNCC1=CC=CC=N1 YPJMOVVQKBFRNH-UHFFFAOYSA-N 0.000 description 1
- FIOIJUCPVZEPFX-UHFFFAOYSA-N 1-(9-ethylcarbazol-3-yl)-n-[(2-methoxyphenyl)methyl]methanamine Chemical compound C=1C=C2N(CC)C3=CC=CC=C3C2=CC=1CNCC1=CC=CC=C1OC FIOIJUCPVZEPFX-UHFFFAOYSA-N 0.000 description 1
- JLCCNYVTIWRPIZ-NRFANRHFSA-N 6-[(1-acetylpiperidin-4-yl)amino]-n-[(2s)-3-(3,4-dihydro-1h-isoquinolin-2-yl)-2-hydroxypropyl]pyrimidine-4-carboxamide Chemical compound C1CN(C(=O)C)CCC1NC1=CC(C(=O)NC[C@H](O)CN2CC3=CC=CC=C3CC2)=NC=N1 JLCCNYVTIWRPIZ-NRFANRHFSA-N 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 230000022963 DNA damage response, signal transduction by p53 class mediator Effects 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 208000031448 Genomic Instability Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 102000004195 Isomerases Human genes 0.000 description 1
- 108090000769 Isomerases Proteins 0.000 description 1
- 102000016397 Methyltransferase Human genes 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 101710084434 Protein arginine N-methyltransferase 1 Proteins 0.000 description 1
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 150000001483 arginine derivatives Chemical class 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- YDGMGEXADBMOMJ-UHFFFAOYSA-N asymmetrical dimethylarginine Natural products CN(C)C(N)=NCCCC(N)C(O)=O YDGMGEXADBMOMJ-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 108091006090 chromatin-associated proteins Proteins 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000034431 double-strand break repair via homologous recombination Effects 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 230000007849 functional defect Effects 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- KCUNTYMNJVXYKZ-SNVBAGLBSA-N methyl (2r)-2-amino-3-(1h-indol-3-yl)propanoate Chemical compound C1=CC=C2C(C[C@@H](N)C(=O)OC)=CNC2=C1 KCUNTYMNJVXYKZ-SNVBAGLBSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- DBSMLQTUDJVICQ-CJODITQLSA-N onametostat Chemical compound NC1=C2C=CN([C@@H]3C[C@H](CCC4=CC=C5C=C(Br)C(N)=NC5=C4)[C@@H](O)[C@H]3O)C2=NC=N1 DBSMLQTUDJVICQ-CJODITQLSA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000012809 post-inoculation Methods 0.000 description 1
- 238000007867 post-reaction treatment Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Engineering & Computer Science (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a PRMT5 inhibitor and application thereof in treating breast cancer, belonging to the technical field of anti-tumor drug research. According to the invention, the Tadalafil is modified through computer aided design, 3 Tadalafil derivative compounds are obtained through screening, and the compounds are named as ZJ-781, ZJ-782 and ZJ-783.ZJ-78 compounds bind PRMT5 and inhibit PRMT5 function. In-vitro and in-vivo experiments further show that the ZJ-78 series compounds can inhibit proliferation of breast cancer cells, promote apoptosis and promote anti-tumor effects of chemotherapeutic drugs such as doxorubicin, cisplatin and olapanib.
Description
Technical Field
The invention belongs to the technical field of anti-tumor drug research, relates to design synthesis of new compounds and anti-tumor effect research, and in particular relates to a PRMT5 inhibitor and application thereof in treating breast cancer.
Background
In recent years, with the frequent occurrence of disease diversification and drug resistance problems, the demand for drugs has been increasing. The development of new drugs often has the risks of long development period, high cost and low success rate. The computer-aided drug design can greatly shorten the drug development time and improve the drug development efficiency in the aspects of drug target spot recognition, active compound screening, compound physical property prediction, compound molecular reconstruction and the like. The molecular docking technology is a core technology of computer-aided drug design, and is based on the structure of biological macromolecules for screening, simulating the three-dimensional structure of the combination of small molecules and biological macromolecules, calculating the combination strength of the small molecules and the biological macromolecules, comprehensively evaluating the combination activity of the small molecules and the biological macromolecules, and has the characteristics of good accuracy and high efficiency.
Protein arginine methyltransferases (protein arginine methyltransferase, PRMTs) are an important class of enzymes that catalyze the methylation of arginine in chromatin proteins, and can catalyze the transfer of methyl groups on S-adenosylmethionine (SAM) to arginine. In eukaryotes, methylated arginine can be divided into three main forms: monomethylarginine (monomethylated arginine, MMA), asymmetric dimethylarginine (asymmetric dimethylarginine, ADMA) and symmetric dimethylarginine (symmetric dimethylarginine, SDMA). The PRMTs family has a total of 9 members and is classified into three types according to the type of methylation that it catalyzes for arginine. Type I PRMTs include 1, 2, 3, 4, 6, catalyze both monomethylation and asymmetric dimethylation of arginine residues, type II PRMTs include 5 and 9, catalyze both monomethylation and symmetric dimethylation, and type III PRMTs include 7, catalyze only monomethylation. PRMT5 is the predominant type II PRMT, having a phosphoglycerate isomerase barrel at the N-terminus, binding to the methylated small protein 50 (WD repeat-containing protein methylosome protein, MEP 50), and a methyltransferase catalytic domain at the C-terminus. PRMT5 is typically present in tetrameric form and forms a heterogeneous complex with its chaperone MEP 50.
PRMT5 is highly expressed in a variety of tumors, and PRMT5 high expression is closely related to patient survival decline. Inhibition of PRMT5 in tumors causes DNA damage, homologous recombination repair-related functional defects, and reduced genomic stability, and may also contribute to activation of P53 signaling pathways, leading to cell cycle arrest and cell death.
Thus, due to the important role of PRMT5 in tumors, its inhibitor research has become a hotspot. Currently, although PRMT5 inhibitors such as GSK3326595, JNJ-64619178 and PF-06939999 have been reported to date to enter the clinical trial phase, no inhibitors are marketed, which is a significant challenge for PRMT5 inhibitor development. Tadalafil (Tadalafil) is a phosphodiesterase 5 (PDE 5) inhibitor, has high efficiency, selectivity and reversibility, and has good effects in improving male erectile dysfunction, treating pulmonary arterial hypertension, prostatic hyperplasia, cardiac hypertrophy and the like. Among the marketed drugs, tadalafil is a novel PRMT5 inhibitor, which can effectively improve the sensitivity of tumor cells to chemotherapeutic drugs such as doxorubicin in breast cancer, but the binding ability with PRMT5 and the antitumor activity thereof are still to be further improved.
Disclosure of Invention
In order to overcome the defects in the prior art, the invention aims to provide a PRMT5 inhibitor and application thereof in treating breast cancer, and can solve the technical problems of low binding capacity between the prior PRMT5 inhibitor and PRMT5 and low anti-tumor activity.
In order to achieve the above purpose, the invention is realized by adopting the following technical scheme:
the invention discloses a PRMT5 inhibitor, which comprises a compound with the following structural formula:
or a pharmaceutically acceptable salt thereof.
The invention discloses application of the PRMT5 inhibitor in preparation of a medicament for treating breast cancer.
Preferably, the agent is an agent that inhibits proliferation of MDA-MB-231 cells, MCF-7 cells, and HCC1937 cells.
The invention discloses application of the PRMT5 inhibitor in preparing a chemotherapeutic drug sensitizer.
Preferably, the PRMT5 inhibitor is capable of enhancing the anti-tumor effect of the chemotherapeutic agents doxorubicin, cisplatin and olaparib.
A pharmaceutical composition comprising a PRMT5 inhibitor as described above and a pharmaceutically acceptable diluent or excipient.
The medicine for treating breast cancer is characterized by comprising the PRMT5 inhibitor and a chemotherapeutic medicine.
Preferably, the chemotherapeutic agent is doxorubicin, cisplatin or olaparib.
Compared with the prior art, the invention has the following beneficial effects:
the invention carries out reconstruction on Tadalafil through computer aided design, firstly, on three parts (piperazine, indole and benzene ring connected with a mother ring) of Tadalafil molecules which are relatively independent, groups containing hetero atoms such as nitrogen, oxygen and sulfur are arranged, so that the Tadalafil molecules and proteins generate more hydrogen bonds; secondly, different alkyl substituents are introduced, so that the Tadalafil molecule and the protein generate more hydrogen bonds and simultaneously enhance the combination of hydrophobic interaction or aromatic groups and the protein; thirdly, changing the chirality of the chiral center, and exploring the influence of the chiral change on the binding process of the Tadalafil molecules and the proteins; fourth, the above modifications were introduced into Tadalafil molecules simultaneously, and the comprehensive effect of these modifications on the binding of Tadalafil molecules to proteins was explored, and 3 Tadalafl derivative compounds were obtained by screening through molecular docking analysis, and named ZJ-781, ZJ-782 and ZJ-783.ZJ-78 compounds bind PRMT5 and inhibit PRMT5 function. In-vitro and in-vivo experiments further show that the ZJ-78 series compounds can inhibit proliferation of breast cancer cells, promote apoptosis and promote anti-tumor effects of chemotherapeutic drugs such as doxorubicin, cisplatin and olapanib.
Drawings
FIG. 1 is a schematic diagram of the synthesis of ZJ-78 series compounds of the present invention;
FIG. 2a is a nuclear magnetic pattern of ZJ-781;
FIG. 2b is a nuclear magnetic pattern of ZJ-782;
FIG. 2c is a nuclear magnetic pattern of ZJ-783;
FIG. 3 shows SPR analysis results of ZJ-78 series compounds of the present invention and PRMT5 protein; wherein, (a) and (b) are respectively ZJ-781 time and concentration effect result graphs; (c) And (d) a graph of the effect results of ZJ-782 time and concentration, respectively; (e) And (f) a graph of the effect results of ZJ-783 time and concentration, respectively;
FIG. 4 is a graph showing that the ZJ-78 series compounds of the invention inhibit the enzymatic function of PRMT 5;
FIG. 5 is a graph showing the results of cell viability of MDA-MB-231, MCF-7, and HCC1937 cells treated with ZJ-78 series compounds at various concentration gradients;
FIG. 6 is a graph showing apoptosis results of 150. Mu.M concentration of ZJ-78 series compounds and Tadalafil treatment of MDA-MB-231 cells;
FIG. 7 shows the results of cell viability assays for MDA-MB-231 and MCF-7 cells treated with ZJ-78 series compounds and Tadalafil with the addition of doxorubicin at corresponding concentration gradients;
FIG. 8 is a graph showing the results of cisplatin testing cell viability by treating MDA-MB-231 and MCF-7 cells with ZJ-78 series compounds and Tadalafil with the addition of corresponding concentration gradients;
FIG. 9 shows the results of the Olaparib test on MDA-MB-231 and MCF-7 cells treated with ZJ-78 series compounds and Tadalafil with the addition of corresponding concentration gradients;
FIG. 10 shows the results of apoptosis assays of MDA-MB-231 treated with ZJ-781 and Tadalafil, respectively, in combination with doxorubicin; wherein, (a) is an Annexin V/PI double-dyeing result; (b) is statistical data;
FIG. 11 is a photograph of a typical MDA-MB-231 subcutaneous tumor material;
FIG. 12 is a tumor growth curve of MDA-MB-231 subcutaneous tumor;
FIG. 13 is a statistical analysis of volume and mass of MDA-MB-231 tumor material; wherein, (a) is tumor volume; (b) is tumor mass;
FIG. 14 shows the detection of proliferation of tumor tissue by Ki67 staining; wherein, (a) the photograph is proliferated; (b) statistical result data.
Detailed Description
In order that those skilled in the art will better understand the present invention, a technical solution in the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings in which it is apparent that the described embodiments are only some embodiments of the present invention, not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the present invention without making any inventive effort, shall fall within the scope of the present invention.
It should be noted that the terms "first," "second," and the like in the description and the claims of the present invention and the above figures are used for distinguishing between similar objects and not necessarily for describing a particular sequential or chronological order. It is to be understood that the data so used may be interchanged where appropriate such that the embodiments of the invention described herein may be implemented in sequences other than those illustrated or otherwise described herein. Furthermore, the terms "comprises," "comprising," and "having," and any variations thereof, are intended to cover a non-exclusive inclusion, such that a process, method, system, article, or apparatus that comprises a list of steps or elements is not necessarily limited to those steps or elements expressly listed but may include other steps or elements not expressly listed or inherent to such process, method, article, or apparatus.
The invention is described in further detail below with reference to the attached drawing figures:
1. ZJ-78 series compound designed and synthesized by utilizing molecular docking technology
First, the binding capacity of the PRMT5 inhibitor to PRMT5 that has been reported was analyzed using Sybyl-X2.0 software. Minimizing energy of all compounds in Sybyl-X2.0 software by using a Tripos force field, taking distance as a dielectric function, taking Gasteiger-Hockel atomic charge as charge, optimizing by using a Powell energy gradient method to obtain the lowest energy conformation, and taking the maximum energy optimization frequency as 10000 and the energy convergence standard as 0.001 kcal.mol -1 Imitate the stable conformation of the molecule in natural systems. The PRMT5: MEP50 complex (PDB: 4 gqb) crystal structure was downloaded from the PDB database, and Sybyl-x 2.0 was introduced for molecular docking. The docking adopts a semi-flexible docking method, and is performed by using a Surflex-Dock module. The total score (Surflex-Dock) takes into account the combination of polarity, hydrophobicity, entropy and solubilityFactors such as the formulation of the agent can reflect the binding affinity of the ligand to the receptor. The greater the score, the more stable the ligand binding to the receptor and the more likely there is an interaction. Butt joint>7 minutes, which indicates that the molecules may have strong binding to the target,>a score of 5 indicates that there may be better binding of the molecule to the target.
The results are shown in Table 1 below, where the binding capacity of Tadalafil to PRMT5 is still further improved compared to inhibitors such as EPZ 015666:
TABLE 1
Name of the name | Score of | Butt joint energy | Polarity of |
CMP-5 | 6.2627 | -0.763 | 0.1182 |
PJ-68 | 6.5977 | -1.5616 | 0 |
EPZ015666 | 6.931 | -1.8667 | 1.003 |
HLCL-61 | 6.5104 | -2.9024 | 0 |
HLCL-65 | 6.3567 | -1.2981 | 0.9458 |
Tadalafil | 6.0896 | -0.8536 | 0.0012 |
Thus, the Tadalafil was modified as follows: firstly, on three relatively independent parts (piperazine, indole and benzene ring connected with a mother ring) of the Tadalafil molecule, installing groups containing hetero atoms such as nitrogen, oxygen and sulfur, so that the Tadalafil molecule and the protein generate more hydrogen bonds; secondly, different alkyl substituents are introduced, so that the Tadalafil molecule and the protein generate more hydrogen bonds and simultaneously enhance the combination of hydrophobic interaction or aromatic groups and the protein; thirdly, changing the chirality of the chiral center, and exploring the influence of the chiral change on the binding process of the Tadalafil molecules and the proteins; fourth, the above modifications were introduced simultaneously into the Tadalafil molecule, and the combined effect of these modifications on the binding of the Tadalafil molecule to the protein was explored.
Then, molecular docking analysis is carried out again on the simulated molecular structure after modification, and 3 compounds with the highest scores are screened out of the 90 obtained compounds, and the docking scores and chemical structures of the compounds named ZJ-781, ZJ-782 and ZJ-783,3 are as follows:
2. chemical synthesis process of ZJ-78 series compounds
The synthesis method is shown in fig. 1, and the specific synthesis steps are as follows:
(1) D-tryptophan methyl ester hydrochloride is treated by sodium bicarbonate to obtain D-tryptophan methyl ester, the D-tryptophan methyl ester hydrochloride is taken as a raw material, dichloromethane (DCM, 10mL/g raw material) is used for dissolving, 1.08 equivalent of aldehyde compound is added into a reaction bottle, nitrogen replacement is sufficient, the reaction system is cooled to about 0 ℃, 2.05 equivalent of trifluoroacetic acid is slowly added dropwise, and the reaction is completed after the addition, and the reaction is carried out at room temperature.
Post-treatment: after the reaction is completed, the reaction solution is adjusted to pH=9 or so, DCM is used for extraction, the organic layers are combined, the mixture is dried by spin-drying and subjected to column chromatography (200-300 meshes of silica gel column chromatography: petroleum ether/ethyl acetate=150/1-80/1), and ZJ-781-1/ZJ-783-1 is obtained by the same synthesis method (the reaction raw materials are not pretreated by sodium bicarbonate, the reaction time is longer, the reaction is more complicated, the isomer exists in the product, the small-polarity product is the target compound, and the yield is basically about 35%).
(2) Putting ZJ-781-1/ZJ-782-1/ZJ-783-1 and 1.2 equivalent sodium bicarbonate into a reaction bottle, adding chloroform (20 mL/g raw material) for dissolution, fully replacing nitrogen, cooling the reaction system to 0 ℃, slowly adding 2.55 equivalent chloroacetyl chloride, after adding, heating to room temperature, and stirring until the reaction is complete (about 1 h);
post-treatment: dilute with DCM, wash with sodium bicarbonate, wash with water, combine the organic layers, dry over anhydrous sodium sulfate, spin dry. ZJ-781-2/ZJ-782-2/ZJ-783-2 can be obtained by the same synthesis method (the post-reaction treatment is relatively simple, and the target product can be obtained by only adding diethyl ether for ultrasonic treatment and filtering, the ZJ-782-2 is not suitable for the treatment by the method, and the direct spin-drying is adopted for the next reaction, so that the yield is basically about 80 percent.
(3) Adding ZJ-781-2/ZJ-782-2/ZJ-783-2 into a reaction bottle, adding methanol for dissolution (35 mL/g raw material), fully replacing nitrogen, adding 2 equivalents of methylamine in the mixture, heating to reflux, and stirring until the reaction is complete (about 16 h);
post-treatment: after the reaction is finished, the ZJ-781 is directly spin-dried and pulped by petroleum ether/ethyl acetate=3/1 to obtain a purer target product, and the ZJ-782/ZJ-783 is purified by column chromatography by the synthetic method, wherein the yield is basically about 75 percent (200-300 mesh silica gel column chromatography: petroleum ether/ethyl acetate=150/1-80/1).
The nuclear magnetic patterns of the three synthesized compounds ZJ-781, ZJ-782 and ZJ-783 are shown in FIG. 2a, FIG. 2b and FIG. 2c respectively.
Affinity assay of ZJ-78 series Compounds with PRMT5 protein
Based on Biacore T200 analysis platform and Surface Plasmon Resonance (SPR) technology, the designed and synthesized ZJ-78 series compound and target protein PRMT5 are subjected to binding affinity analysis. The medicine Tadalafil is MCE company product, catalog number is HY-90009A. PRMT5/MEP50 purified protein was an Active Motif company product, catalog number 31521. The diluted concentrations of Tadalafil were in order: 31.75 62.5, 125, 250, 500 μm. Referring to FIG. 3, the results show that the ZJ-78 series compounds have better affinity with PRMT5 protein.
Functional analysis of PRMT5 enzyme inhibition by ZJ-78 series Compounds
MDA-MB-231 breast cancer cell lines were treated with various concentrations (50. Mu.M, 100. Mu.M, and 150. Mu.M) of ZJ-78 series compounds to detect the expression level of the substrate H3R8me2s downstream of PRMT 5. Western blotting results are shown in FIG. 4, and the results show that the level of total H3R8me2s in the cells is significantly reduced, and the inhibition is dose-dependent. The results indicate that ZJ-78 series compounds inhibit PRMT5 enzymatic activity.
ZJ-78 series compounds can promote inhibition of breast cancer cell proliferation and promote apoptosis
To further compare the antitumor ability of ZJ-78 series compounds with that of Tadalafil, treatment of different types of breast cancer cell lines with these 3 compounds and Tadalafil, CCK8 assays found significant inhibition of cell viability in MDA-MB-231 cells, MCF-7 cells, and HCC1937 cells, with the inhibition of cell proliferation by ZJ-781 being most pronounced (FIG. 5).
In addition, the effect of ZJ-78 series compounds on apoptosis was also analyzed by an Annexin V/PI double staining method in the MDA-MB-231 cell line. The results show that the ZJ-78 series compounds can promote the apoptosis of MDA-MB-231 cells to different degrees, and the promotion effect of the ZJ-781 on the apoptosis is most obvious (figure 6)
In FIG. 5, MDA-MB-231, MCF-7 and HCC1937 cells were treated with ZJ-78 series compounds and Tadalafil at various concentration gradients, and after 48h, the cell viability was examined by CCK8 method. In FIG. 6, MDA-MB-231 cells were treated with ZJ-78 series compounds and Tadalafil at 150. Mu.M concentration, and apoptosis was detected by the Annexin V/PI method after 48 h. * P <0.05, < P <0.01, < P <0.001, < P <0.0001, n.s., not signature. Bars = means ± SEM.
ZJ-78 series compounds can improve the sensitivity of breast cancer cells to chemotherapeutics in vitro
Since the difference between the ZJ-78 series compound and the Tadalafil is most obvious when the cells are treated at the concentration of 150 mu M, the concentration of the ZJ-78 series compound and the Tadalafil is set to be 150 mu M, and a concentration gradient of doxorubicin treatment is established on the basis, and the influence on the cell viability after the compound is combined with the doxorubicin is detected by a CCK8 method. The results showed that at a doxorubicin treatment concentration of 0.2 μg/ml, both ZJ-78 series and Tadalafil further enhanced the inhibition of cell viability by doxorubicin, but that the inhibition of cell viability was more pronounced following the combination of ZJ-781 with doxorubicin (FIG. 7). Similarly, ZJ-78 series of compounds may also promote inhibition of cell viability by cisplatin and Olaparib (FIGS. 8 and 9).
In addition, the effect of ZJ-781 and Tadalafil on MDA-MB-231 cell apoptosis when combined with doxorubicin, respectively, was also examined. The results showed that after the addition of Tadalafil and compound ZJ-781, the proportion of living cells was significantly reduced compared to doxorubicin alone, and the proportion of cells undergoing early and late apoptosis was significantly increased, however, the PI-single positive necrotic cell population was not significantly changed after the addition of the compound. Overall, ZJ-781 promotes apoptosis in combination with doxorubicin, and the effect is stronger than that of doxorubicin alone and Tadalafil in combination with doxorubicin. As a result, referring to FIG. 10, 150. Mu.M of ZJ-781 and Tadalafil were treated with 0.2. Mu.g/ml doxorubicin, respectively, and after 48 hours, apoptosis was detected by the Annexin V/PI double-staining method. * P <0.05, < P <0.01, < P <0.001, < P <0.0001, n.s., not signature. Bars = means ± SEM.
7. The compound ZJ-781 can improve the sensitivity of breast cancer cells to chemotherapeutics in vivo
MDA-MB-231 cells are inoculated subcutaneously in nude mice, ZJ-781 with the best efficacy in ZJ-78 series compounds is selected, and the combination of the ZJ-781 with chemotherapeutic drugs of doxorubicin, cisplatin and olapanib is used for analyzing the anti-tumor effect of PRMT5 inhibitors in vivo. On day 10 post-inoculation, mice were given 8 different intervention modes: control group, ZJ-781, doxorubicin, ZJ-781+doxorubicin, cisplatin, ZJ-781+cisplatin, olaparib, ZJ-781+Olaparib. Wherein, the compound ZJ-781 is infused once per day at a dose of 2mg/kg, doxorubicin is injected once per week at a dose of 2mg/kg for tail vein, olaparib is injected once per day at 50mg/kg for abdominal cavity, cisplatin is injected once per 3 days at 2.5mg/kg for abdominal cavity, and the materials are taken and analyzed on day 31 after inoculation. Similar to the results of in vitro experiments, ZJ-781 alone resulted in a reduction in tumor growth, but when ZJ-781 was used in combination with chemotherapeutic agents, the efficacy of the chemotherapeutic agents was further enhanced and tumor growth was reduced (FIGS. 11, 12 and 13). Meanwhile, ki67 immunohistochemical results showed that ZJ-781 was further inhibited in proliferation capacity of tumor cells when combined with chemotherapeutic drugs (fig. 14).
In summary, the present invention is based on Tadalafil design and synthesis of 3 PRMT5 inhibitors, namely ZJ-781, ZJ-782 and ZJ-783. The 3 PRMT5 inhibitors can be effectively combined with PRMT5, inhibit the enzyme activity of PRMT5, inhibit the proliferation of breast cancer cells, promote apoptosis, and enhance the anti-tumor effect of chemotherapeutic drugs such as doxorubicin, cisplatin and olaparib. Wherein, the ZJ-781 has the most obvious anti-tumor effect and can play a role in sensitization of chemotherapeutic drugs in vivo.
The above is only for illustrating the technical idea of the present invention, and the protection scope of the present invention is not limited by this, and any modification made on the basis of the technical scheme according to the technical idea of the present invention falls within the protection scope of the claims of the present invention.
Claims (3)
1. The application of PRMT5 inhibitors in preparing medicaments for treating breast cancer is characterized in that the PRMT5 inhibitors are compounds shown in the following structural formula:
or a pharmaceutically acceptable salt thereof.
2. The use of claim 1, wherein the agent is an agent that inhibits proliferation of MDA-MB-231 cells, MCF-7 cells, and HCC1937 cells.
3. The application of PRMT5 inhibitors in preparing chemotherapeutic drug sensitizers is characterized in that the PRMT5 inhibitors are compounds shown in the following structural formula:
or a pharmaceutically acceptable salt thereof;
the chemotherapeutic drugs are doxorubicin, cisplatin and olapanib, and the PRMT5 inhibitor can enhance the antitumor effect of the chemotherapeutic drugs doxorubicin, cisplatin and olapanib.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210334932.4A CN114558014B (en) | 2022-03-31 | 2022-03-31 | PRMT5 inhibitor and application thereof in treating breast cancer |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210334932.4A CN114558014B (en) | 2022-03-31 | 2022-03-31 | PRMT5 inhibitor and application thereof in treating breast cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114558014A CN114558014A (en) | 2022-05-31 |
CN114558014B true CN114558014B (en) | 2024-01-30 |
Family
ID=81718931
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210334932.4A Active CN114558014B (en) | 2022-03-31 | 2022-03-31 | PRMT5 inhibitor and application thereof in treating breast cancer |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114558014B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116211869B (en) * | 2022-12-07 | 2023-08-01 | 浙江省肿瘤医院 | Pharmaceutical mixture containing DNA damage repair inhibitor, mixing method and application |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110464726A (en) * | 2019-08-20 | 2019-11-19 | 中国人民解放军第四军医大学 | Application of the Tadalafei as protein arginine transmethylase PRMT5 inhibitor |
CN111297868A (en) * | 2020-04-05 | 2020-06-19 | 黄泳华 | Use of a composition comprising a heterocyclic compound for the manufacture of a medicament for the treatment of phosphodiesterase mediated diseases |
CN112007032A (en) * | 2020-09-16 | 2020-12-01 | 厦门大学 | Application of compound in preparation of small molecule inhibitor or cancer treatment drug, small molecule inhibitor and cancer treatment drug |
-
2022
- 2022-03-31 CN CN202210334932.4A patent/CN114558014B/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110464726A (en) * | 2019-08-20 | 2019-11-19 | 中国人民解放军第四军医大学 | Application of the Tadalafei as protein arginine transmethylase PRMT5 inhibitor |
CN111297868A (en) * | 2020-04-05 | 2020-06-19 | 黄泳华 | Use of a composition comprising a heterocyclic compound for the manufacture of a medicament for the treatment of phosphodiesterase mediated diseases |
CN112007032A (en) * | 2020-09-16 | 2020-12-01 | 厦门大学 | Application of compound in preparation of small molecule inhibitor or cancer treatment drug, small molecule inhibitor and cancer treatment drug |
Non-Patent Citations (2)
Title |
---|
Ashraf H. Abadi等.Synthesis, molecular modeling and biological evaluation of novel tadalafil analogues as phosphodiesterase 5 and colon tumor cell growth inhibitors,new stereochemical perspective.European Journal of Medicinal Chemistry.2010,(第45期),第1278-1286页,尤其是Scheme 3. * |
Goverdhan Gilla等.Synthesis and characterization of related substances and metabolite of tadalafil, a PDE-5 inhibitor.Organic Communications.2013,第6卷(第1期),第12-22页. * |
Also Published As
Publication number | Publication date |
---|---|
CN114558014A (en) | 2022-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008030892A2 (en) | Drug design for tubulin inhibitors, compositions, and methods of treatment thereof | |
CN110437291B (en) | Pentaacetyl geniposide cyclohexylamide with uric acid reducing activity and preparation method and application thereof | |
CN114558014B (en) | PRMT5 inhibitor and application thereof in treating breast cancer | |
CN104371009B (en) | GnRH polypeptide methotrexate (MTX)s conjugate, preparation method and the usage | |
Moya-Garzon et al. | New salicylic acid derivatives, double inhibitors of glycolate oxidase and lactate dehydrogenase, as effective agents decreasing oxalate production | |
CN109320557A (en) | 99mTc(CO)3The Pa Boxini derivative and preparation method and application containing isonitrile of core label | |
Lu et al. | Design, synthesis and biological evaluation of fluorinated selective estrogen receptor degraders (FSERDs)---A promising strategy for advanced ER positive breast cancer | |
Xu et al. | Design, synthesis, and bioactivity evaluation of macrocyclic benzo [b] pyrido [4, 3-e][1, 4] oxazine derivatives as novel Pim-1 kinase inhibitors | |
US11369602B2 (en) | Use of tadalafil as protein arginine methyltransferase (PRMT5) inhibitor | |
Katayama et al. | Design, synthesis, and optimization of a series of 2-azaspiro [3.3] heptane derivatives as orally bioavailable fetal hemoglobin inducers | |
CN109369620A (en) | Pyridine compounds and their and preparation method thereof and anti-gastric cancer application | |
CN111253308B (en) | Small molecule inhibitor of protein kinase A and preparation method and application thereof | |
CN114437178B (en) | BIDBH3 mimic peptide compound taking PTP1B as target point, and preparation method and application thereof | |
Cohen et al. | Distribution of radioactivity and metabolism of formic acid 2-[4-(5-nitro-2-furyl)-2-14C-2-thiazolyl] hydrazide following oral administration to rats and mice | |
CN113234052A (en) | Extracellular regulatory protein kinase inhibitor and preparation method and application thereof | |
CN110078768A (en) | The technetium-99 m labeled Pa Boxini derivative and preparation method and application containing HYNIC | |
LU500160B1 (en) | Novel BH3 Mimetic Peptide Compounds Targeting PTP1B, Preparation Method and Application Thereof | |
CN114890928B (en) | Isothiocyanate derivative and preparation method and application thereof | |
CN115594675B (en) | Beta-carbalin-cinnamic acid skeleton derivative and preparation method and application thereof | |
Bailly et al. | Interaction of fumigaclavine C with High Mobility Group Box 1 protein (HMGB1) and its DNA complex: a computational approach | |
CN109400597B (en) | VEGFR-2 inhibitor ABT-869-based protein degradation targeting chimera and preparation method and application thereof | |
CN108976236A (en) | A kind of deuterated PARP inhibitor, its salt, preparation method and the usage | |
CN109293663B (en) | KDM5B inhibitor and preparation method thereof | |
CN111170943B (en) | Benzo [ f ] cyclopentano [ c ] quinoline derivatives and use thereof | |
CN111875606B (en) | Purine compound obtained based on virtual docking and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |